Drug companies may provide information directly to EU patients but under strict conditionsBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c6883 (Published 30 November 2010) Cite this as: BMJ 2010;341:c6883
- Rory Watson
Drug companies will be able to provide information to the public on prescription drugs but only under strict conditions, according to draft legislation overwhelmingly adopted by the European parliament on 24 November.
The new measures would enable patients in European Union countries to receive data on a drug’s characteristics and the disease or condition for which it is designed. Companies would be allowed to provide basic non-promotional information such as product characteristics in package leaflets and an accessible version of a drug’s assessment report. Patients would be able to receive more specific answers on request. All information would require prior authorisation from national authorities. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial